Insmed (INSM) – Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Insmed (NASDAQ: INSM):

• 10/12/2026 – Insmed had its “buy” rating reaffirmed by Bank of America Corporation. They now have a $207.00 price target on the stock.
• 10/12/2026 – Insmed was downgraded by Wolfe Research from “outperform” to “peer perform”.
• 10/12/2026 – Insmed had its “buy” rating reaffirmed by HC Wainwright. They now have a $220.00 price target on the stock.
• 10/8/2026 – Insmed had its “buy” rating reaffirmed by UBS Group AG.
• 10/6/2026 – Insmed had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/30/2026 – Insmed had its price target lowered by Barclays PLC from $237.00 to $207.00. They now have an “overweight” rating on the stock.
• 9/24/2026 – Insmed is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $188.00 price target on the stock.
• 9/24/2026 – Insmed is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $188.00 price target on the stock.
• 9/15/2026 – Insmed had its “buy” rating reaffirmed by Roth Capital. They now have a $198.00 price target on the stock, down from $212.00.

Insider Transactions at Insmed

In related news, COO Roger Adsett sold 239,850 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the transaction, the chief operating officer owned 98,744 shares in the company, valued at $13,159,612.88. The trade was a 70.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David R. Brennan sold 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the sale, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.10% of the stock is currently owned by corporate insiders.

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.